Cloning,expression,and immunological characterization of two novel profilins from Artemisia annua  

作　　者：Qiao-Li Hu Li-Xiang Zhu Zhi-Qiang Xu Chen Pan Qiu-Min Zhong Jin-Lyu Sun Ji-Fu Wei 

机构地区：[1]Research Division of Clinical Pharmacology,The First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China [2]School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing,Jiangsu 211198,China [3]School of Pharmacy,Nanjing Medical University,Nanjing,Jiangsu 211166,China [4]The Department of Pharmacology,The First Affiliated Hospital of Gannan Medical University,Ganzhou,Jiangxi 341000,China [5]Department of Allergy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China

出　　处：《Chinese Medical Journal》2021年第10期1224-1226,共3页中华医学杂志（英文版）

基　　金：supported by grants from the National Natural Science Foundation of China(Nos.81871265,81771725,U1832212,and 81971515)。

摘　　要：The incidence of allergic disease has increased rapidly in recent decades in both developed and developing countries.[1]In China,pollen of Artemisia is one of the most important outdoor allergen as reported by the first national pollen survey across all provinces.[2]Artemisia pollen has been found to be an important cause of seasonal asthma.[3]Artemisia vulgaris and Artemisia annua are the most important Artemisia species in China.A.vulgaris mainly grows in western regions,while A.annua is abundant in the densely populated northern and eastern regions.[4]Immunoglobulin E(IgE)antibodies play a key role in allergy diseases.They are synthesized and released by B cells and bind to high-affinity IgE receptors on mast cells or basophils.[5]Once the patients are exposed to corresponding allergens,the effector cells will be triggered and then release its mediator,leading to an allergic inflammation.

关 键 词：ALLERGIC annua RELEASE 

分 类 号：R392[医药卫生—免疫学]